Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Profit before exceptional items and tax rose 7.82% to Rs 4,302.90 crore from Rs 3,990.77 crore a year earlier. The company reported exceptional items of Rs 204.09 crore during the quarter, including a charge of Rs 167 crore towards due diligence, legal, filing and other transaction-related expenses incurred for the proposed acquisition of Organon & Co. Sun Pharma said additional acquisition-related costs are expected in the coming quarters.
EBITDA increased 2.7% year-on-year to Rs 4,417.7 crore in Q1 FY27. However, the EBITDA margin contracted to 28.9% in Q1 FY27 from 31.1% in the year-ago period.
India continued to be the company's strongest market, with formulation sales rising 16% to Rs 5,474.9 crore, contributing 36.1% of consolidated sales.
In the United States, formulation sales declined 9.7% year-on-year to $427 million, as growth in the Innovative Medicines portfolio was partly offset by weakness in the generics business. The US business accounted for around 26.6% of consolidated sales.
Emerging Markets formulation sales rose 4.2% to $311 million, contributing 19.4% of total consolidated sales, while formulation sales in the Rest of the World stood at $218 million, accounting for 13.6% of consolidated sales.
Global Innovative Medicines sales climbed 12.8% YoY to $351 million during the quarter and contributed 21.9% of consolidated sales.
Research and development expenditure stood at Rs 826.4 crore, representing 5.4% of sales.
Kirti Ganorkar, managing director, said, “Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027.”
Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to the global market. It is the largest pharmaceutical company in India.
The counter declined 0.62% to close at Rs 1,988.25 on the BSE.
Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 2033.1, up 1.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 24401.75. The Sensex is at 78202.2, up 0.35%. Sun Pharmaceutical Industries Ltd has added around 8.94% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 5.81% in last one month and is currently quoting at 26346.05, up 1.14% on the day. The volume in the stock stood at 10.53 lakh shares today, compared to the daily average of 23.07 lakh shares in last one month.
The benchmark August futures contract for the stock is quoting at Rs 2037.9, up 1.53% on the day. Sun Pharmaceutical Industries Ltd is up 24.75% in last one year as compared to a 0.67% fall in NIFTY and a 21.06% fall in the Nifty Pharma index.
The PE of the stock is 163.06 based on TTM earnings ending March 26.
Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma.
The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.
Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing.
“South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals,' said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.
Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—allowing flexible, once-weekly dosing.
“South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals,' said Aalok Shanghvi, chief operating officer, Sun Pharma.
The company said that South Africa faces a growing burden of type 2 diabetes, driven in part by rapid urbanization and changing lifestyles. This rising prevalence places significant pressure on patients and the healthcare system. Improving access to effective therapies is therefore an important component of addressing this national health challenge.
The company had reported a 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026.
The scrip rose 0.46% to currently trade at Rs 1,949 on the BSE.
Investors will continue to monitor developments in the US-Iran conflict, movements in crude oil prices, the ongoing Q1 earnings season, corporate business updates, and the progress of the southwest monsoon for further cues on market direction.
Private bank shares recovered after falling in the previous trading session.
At 11:25 IST, the barometer index, the S&P BSE Sensex advanced 479.41 points or 0.64% to 77,545.01. The Nifty 50 index added 133.95 points or 0.56% to 24,186.
In the broader market, the BSE 150 MidCap Index jumped 0.62% and the BSE 250 SmallCap Index climbed 0.97%.
The market breadth was strong. On the BSE, 2,495 shares rose and 1,346 shares fell. A total of 219 shares were unchanged.
IPO Update:
The initial public offer (IPO) of Alphine Texoworld received bids for 55.32 lakh shares as against 1.20 crore shares on offer, as per NSE data as of 11:21 hours on Wednesday (15 July 2026). The issue was subscribed 0.46 times.
The issue opened for bidding on Tuesday (14 July 2026) and it will close on Thursday (16 July 2026). The price band of the IPO is fixed between Rs 100 to Rs 105 per share. The minimum order quantity is 142 equity shares.
SBI Funds Management IPO received bids for 2.39 crore shares as against 14.51 crore shares on offer, according to stock exchange data at 11:21 IST on Wednesday (15 July 2026). The issue was subscribed 1.17 times.
The issue opened for bidding on 14 July 2026 and it will close on 16 July 2026. The price band of the IPO is fixed between Rs 545 and 574 per share. An investor can bid for a minimum of 26 equity shares and multiples thereof.
Buzzing Index:
The Nifty Private Bank index advanced 1.01% to 28,198. The index declined 0.85% in the past trading session.
Bandhan Bank (up 5.69%), IndusInd Bank (up 2.47%), Axis Bank (up 1.39%), ICICI Bank (up 1.13%) and HDFC Bank (up 0.93%), IDFC First Bank (up 0.71%), RBL Bank (up 0.57%), Kotak Mahindra Bank (up 0.51%), Yes Bank (up 0.51%) and Federal Bank (up 0.12%) advanced.
Stocks in Spotlight:
Sun Pharmaceutical Industries rose 0.89%. The company announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa.
Belrise Industries rose 2.45% after the company announced the launch of its qualified institutional placement (QIP) issue and fixed the floor price at Rs 230.79 per equity share. The floor price of Rs 230.79 per share is at a discount of 0.65% to the scrip's previous closing price of Rs 232.30 on the BSE.
Global Markets:
Asian markets advanced on Wednesday after a surprise slowdown in U.S. inflation scaled back market expectations for interest rate hikes, while oil took a breather as the U.S. scrapped a plan to levy shipping through the Strait of Hormuz.
U.S. President Donald Trump reimposed a naval blockade of Iranian ports on Tuesday and threatened to attack power plants and bridges next week unless Iran resumes negotiations to end their conflict, though he scrapped a plan for a 20% fee on shipping through Hormuz.
Meanwhile, China’s economy in the second quarter expanded at its weakest pace since the fourth quarter of 2022. These figures reinforce calls for policy stimulus as an accelerating slide in investments deepened the strain on growth, while consumption stayed subdued.
Gross domestic product growth came in at 4.3% in the April to June period, data from the National Statistics Bureau showed Wednesday, missing widely reported forecast for 4.5% growth, and slowing from 5% in the first quarter.
That second-quarter growth came below Beijing’s full-year growth target range of 4.5% to 5%, the least ambitious goal in decades, amid tensions with trade partners, including the U.S. and the European Union, and sluggish domestic demand.
The S&P 500 and the Nasdaq advanced on Tuesday as solid big bank results and a cooler-than-expected inflation report boosted risk appetite amid rising Middle East tensions.
The U.S. headline consumer price index fell 0.4% in June, its first decline since the COVID-19 pandemic, while annualised core inflation of 2.6% compared with widely reported expectations for 2.8%.
The Labor Department's Consumer Price Index showed inflation cooled more than analysts expected in June, largely due to abating energy price pressures amid last month's signs of progress in U.S.-Iran peace negotiations.
Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 24472.4. The Sensex is at 78420.16, up 0.17%. Sun Pharmaceutical Industries Ltd has added around 7.01% in last one month.
Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 6.88% in last one month and is currently quoting at 25866.25, down 0.22% on the day. The volume in the stock stood at 10.77 lakh shares today, compared to the daily average of 19.54 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1917.1, down 0.05% on the day. Sun Pharmaceutical Industries Ltd is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma index.
The PE of the stock is 152.92 based on TTM earnings ending March 26.